secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eledon Pharmaceuticals, Inc. (ELDN)
CIK:        0001404281
Form:       8-K
Filed at:   2024-05-07T23:59:59+00:00
Accession:  0000950170-24-053934
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eledon raises $50M in oversubscribed private placement; tegoprubart advances in transplant trials
--------------------------------------------------------------------------------

- Gross proceeds ~$50M from 13.1M shares at $2.37/sh and 7.99M pre-funded warrants at $0.001/sh.
- Financing led by BVF Partners; expected to close week of May 6; net proceeds for pre-commercial activities and tegoprubart development.
- First participant dosed in islet cell transplant trial with tegoprubart for type 1 diabetes at University of Chicago.
- Updated Phase 1b kidney transplant data: mean eGFR >60 mL/min after day 30; two subjects at 12 months had eGFR >90.
- No graft loss or death in Phase 1b; three discontinuations (hair loss/fatigue, viral infection, rejection).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1404281/000095017024053934/0000950170-24-053934-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1404281/000095017024053934/eldn-20240506.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-053934

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer